Inhalation and Nasal Spray Generic Drugs Market Report 2025

The inhalation and nasal spray generic drugs market size has grown strongly in recent years. It will grow from $29.71 billion in 2024 to $31.84 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to rising respiratory disorders, cost-effective alternatives, government initiatives to promote generics, market entry of generic manufacturers, generic switching policies, regulatory support for generics.

The inhalation and nasal spray generic drugs market size is expected to see strong growth in the next few years. It will grow to $43.48 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to growing aging population, expanding generic pipeline, pharmacy and retailer initiatives, global respiratory disease burden, biosimilar competition, patient preference for generic alternatives. Major trends in the forecast period include advancements in inhalation drug delivery systems, focus on biosimilar nasal sprays, collaborations and partnerships, patient-centric design of inhalers, shift towards OTC nasal sprays.

The increasing prevalence of chronic respiratory diseases worldwide is expected to drive the growth of inhalation and nasal spray generic drugs. Chronic respiratory conditions impact the airways and other structures of the lungs. For example, in June 2023, the Australian Institute of Health and Welfare, an Australia-based national agency, reported that nearly one-third (30%) of Australians, or 7.5 million individuals, have been diagnosed with chronic respiratory diseases. Consequently, the rising incidence of chronic respiratory diseases globally is set to contribute to the expansion of this market.

The rising number of smokers is anticipated to drive the growth of the inhalation and nasal spray generic drugs market in the coming years. Smokers are individuals who engage in smoking tobacco products, including cigarettes, cigars, or pipes, which involves inhaling smoke produced from burning tobacco. Inhalation and nasal spray generic drugs are utilized to manage respiratory conditions commonly associated with smoking, such as chronic obstructive pulmonary disease (COPD) and asthma. For instance, in May 2023, the Centers for Disease Control and Prevention, a U.S.-based government agency, reported that approximately 3.08 million middle and high school students in the United States use at least one tobacco product, and an estimated 28.3 million people smoke cigarettes. Furthermore, around 1,600 U.S. youths under the age of 18 smoke their first cigarette each day. Additionally, in July 2022, Statistics Canada, a Canadian government agency, noted a 5.8% increase in cigarette production compared to June 2021, and the total number of cigarettes sold rose by 1.3% from May 2022, reaching 1.4 billion in June 2022. Thus, the growing number of smokers is driving the expansion of the inhalation and nasal spray generic drugs market.

Strategic partnerships and collaborations have become significant trends in the inhalation and nasal spray generic drugs market. Major players in this sector are focusing on such alliances to strengthen their market position. For example, in February 2022, Glenmark Pharmaceuticals Limited, an integrated research-based global pharmaceutical company based in India, partnered with SaNOtize, a Canada-based biotech firm. Through this collaboration, they aimed to launch the Nitric Oxide Nasal Spray (NONS) to treat COVID-19 in adult patients in India.

Innovation and technological advancements stand as pivotal strategies adopted by major companies in the inhalation and nasal spray generic drugs market to maintain and strengthen their foothold. GSK's introduction of Trelegy Ellipta in April 2022 exemplifies this trend. The Ellipta inhaler, a portable device, facilitates precise delivery of medications to the lungs, offering a single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD) and asthma treatment. Notably, the inhaler's capacity to contain three distinct drugs in foil packaging - a corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta2-adrenergic agonist - signifies an innovative approach to combination therapy, catering to respiratory health needs efficiently.

In March 2022, Sandoz International GmbH, a Swiss-based company specializing in the development, manufacturing, and distribution of generic pharmaceuticals, completed the acquisition of Coalesce Product Development for an undisclosed sum. Through this acquisition, Sandoz has gained access to Coalesce's assets and capabilities, empowering the Novartis division to enhance its existing range of respiratory medications and notably improve patient access to advanced therapies. Coalesce Product Development, based in the UK, is known for its development of a diverse portfolio of innovative inhalation devices.

Major companies operating in the inhalation and nasal spray generic drugs market are Teva Pharmaceuticals Inc., Sandoz International GmbH, Akorn Operating Company LLC, Cipla Inc., Apotex Inc., Impax Laboratories LLC, Bausch Health Companies Inc., Hikma Pharmaceuticals PLC, Lupin Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Zydus Lifesciences Ltd., Torrent Pharmaceuticals Limited, Glenmark Pharmaceuticals Limited, Jubilant Biosys Limited, Alembic Pharmaceuticals Limited, Laurus Labs Limited, Macleods Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Wockhardt Limited, Alkem Laboratories Limited, Unichem Laboratories Limited, Indoco Remedies Limited, Natco Pharma Limited, Aesica Pharmaceuticals Limited, Labiana Pharmaceuticals S.L.U., Summit Biosciences Inc.

North America was the largest region in the inhalation and nasal spray generic drugs market in 2024 and is expected to be the fastest-growing region in the forecast period. The regions covered in the inhalation and nasal spray generic drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the inhalation and nasal spray generic drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Inhalation and nasal spray generic drugs serve as primary delivery methods for treating asthma and chronic obstructive pulmonary disease (COPD). Nasal sprays, liquid medications sprayed into the nose, specifically target nasal congestion, providing relief from stuffiness. On the other hand, inhalers are devices used to administer medication in spray form, which is then breathed in through the mouth or nose.

Within the realm of inhalation and nasal spray generic drugs, various drug classes exist, including corticosteroids, bronchodilators, antihistamines, combinations, and decongestant sprays. Corticosteroids, comprising glucocorticoids and mineralocorticoids, belong to a group of steroid hormones produced by the adrenal cortex. They are utilized to alleviate inflammation, severe allergies, skin conditions, asthma, or arthritis. These drugs find application in treating diverse conditions such as asthma, COPD, allergic rhinitis, among others. Patients benefiting from these drugs span across geriatric, adult, and pediatric demographics. The end users encompass hospitals, home care setups, and various other end-user environments.

The inhalation and nasal spray generic drugs market research report is one of a series of new reports that provides inhalation and nasal spray generic drugs market statistics, including inhalation and nasal spray generic drugs industry global market size, regional shares, competitors with a inhalation and nasal spray generic drugs market share, detailed inhalation and nasal spray generic drugs market segments, market trends and opportunities, and any further data you may need to thrive in the inhalation and nasal spray generic drugs industry. The inhalation and nasal spray generic drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The inhalation and nasal spray generic drugs market consists of sales of fluticasone, budesonide, beclomethasone, albuterol, epinephrine, phenylephrine hydrochloride, oxymetazoline and hydrochloride. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.